Daniel Goodman

Daniel covers a wide range of biotech inventions, including therapeutic antibodies, antisense compounds, transgenic animals and cell‑based therapies. He has a sizable European prosecution practice, and regularly advocates for clients in offensive and defensive EPO opposition proceedings. Recently, Daniel was one of a trio of Carpmaels attorneys that represented Novartis in G1/22, an Enlarged Board of Appeal referral that fundamentally changed how the EPO examines priority rights.

Daniel has a particular interest in antibody-related inventions. His practice has encompassed a slew of patents in the anti‑IL12, anti-IL23, anti-CD47 and anti-CD117 fields. Daniel relishes building and defending patent portfolios that protect the innovation associated with the various stages of antibody product development. New platforms, formats, targets, leads, formulations and uses each come with their own particular considerations and challenges.

More generally, Daniel enjoys collaborating with the firm’s Dispute Resolution and Transactions teams to provide clients with integrated IP advice on commercially important matters such as freedom to operate, due diligence, licensing and infringement.

Daniel joined the firm as a trainee in 2012. When qualifying as a patent attorney, he was awarded a Distinction in the Certificate in Intellectual Property Law. In 2017, Daniel qualified as a Charted and European patent attorney and proceeded to obtain the IP Litigation Certificate. Daniel was named as a Rising Star in IP by Managing IP in 2019, 2020, 2021, 2022 and 2023.

Before entering the patent profession, Daniel graduated with a first class degree in Natural Sciences from Cambridge University, specialising in Immunology. During his studies he was awarded college scholarships for excellence in examinations. Daniel was sponsored through his undergraduate course by a biotech company, where he had a recurring summer placement as a research assistant. He then moved to Imperial College London for his PhD in Molecular Biology, in which he focussed on the characterisation of a stress-signalling pathway in Saccharomyces cerevisiae.

In his spare time, Daniel enjoys travelling and going on outings with his young family.